Spontaneous object recognition and its relevance to schizophrenia: A review of findings from pharmacological, genetic, lesion and developmental rodent models

Psychopharmacology

Volumn 220, Issue 4, 2012, Pages 647-672

  Lyon, L ^a,b   Saksida, L M ^a,b   Bussey, T J ^a,b  

^a UK   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

COMT; Dopamine; Glutamate; Memory; Neuregulin; Novel; Schizophrenia; Spontaneous object recognition

Indexed keywords

1,4 DIAZABICYCLO[3.2.2]NONANE 4 CARBOXYLIC ACID 4 BROMOPHENYL ESTER; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4 AMINOBUTYRIC ACID; 4 CHLORO N (3 QUINUCLIDINYL)BENZAMIDE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; A 412997; ACETYLCHOLINE; ARIPIPRAZOLE; ASENAPINE; BUNGAROTOXIN RECEPTOR STIMULATING AGENT; CANNABINOID; CATECHOL METHYLTRANSFERASE; CLOZAPINE; COLURACETAM; DONEPEZIL; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMIC ACID; HALOPERIDOL; IDALOPIRDINE; N [4 (2 CYANOPHENYL) 1 PIPERAZINYLMETHYL] 3 METHYLBENZAMIDE; N [4 [2 (8 CYANO 1,3A,4,9B TETRAHYDRO 1 BENZOPYRANO[3,4 C]PYRROL 2(3H) YL)ETHYL]PHENYL]ACETAMIDE; NEU DIFFERENTIATION FACTOR; NICOTINIC AGENT; PHYSOSTIGMINE; RACLOPRIDE; RISPERIDONE; SEROTONIN; SEROTONIN 6 ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; NEUROLEPTIC AGENT;

BRAIN DAMAGE; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; CONSTRUCT VALIDITY; DOPAMINERGIC SYSTEM; DRUG EFFECT; GABAERGIC SYSTEM; GENE MUTATION; HIPPOCAMPUS; HUMAN; LOW DRUG DOSE; NONHUMAN; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RECOGNITION; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SPONTANEOUS OBJECT RECOGNITION; ANIMAL; DISEASE MODEL; GENETICS; MOUSE; PATHOLOGY; PHYSIOLOGY; RAT; RODENT; SPECIES DIFFERENCE; TIME;

ANIMALS; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HUMANS; MICE; RATS; RECOGNITION (PSYCHOLOGY); RODENTIA; SCHIZOPHRENIA; SPECIES SPECIFICITY; TIME FACTORS;

EID: 84871369299     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2536-5     Document Type: Review

References (291)

1. Abe H, Ishida Y, Iwasaki T. (2004) Perirhinal N-methyl-D-aspartate and muscarinic systems participate in object recognition in rats. Neurosci Lett 356:191-194
2. Adler CM, Malhotra AK, Elman I, Goldberg T., Egan M, Pickar D, Breier A. (1999) Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 156:1646-1649
3. Aggleton JP, Brown M.W. (2006) Interleaving brain systems for episodic and recognition memory. Trends Cogn Sci 10:455-463
4. Aggleton JP, Hunt PR, Rawlins J.N. (1986) The effects of hippocampal lesions upon spatial and non-spatial tests of working memory. Behav Brain Res 19:133-146
5. Aggleton JP, Keen S, Warburton E.C., Bussey T.J. (1997) Extensive cytotoxic lesions involving both the rhinal cortices and area TE impair recognition but spare spatial alternation in the rat. Brain Res Bull 43:279-287
6. Aisa B, Tordera R, Lasheras B., Del Rio J, Ramirez M.J. (2008) Effects of maternal separation on hypothalamic-pituitary-adrenal responses, cognition and vulnerability to stress in adult female rats. Neuroscience 154:1218-1226
7. Akhondzadeh S, Gerami M, Noroozian M., Karamghadiri N, Ghoreishi A, Abbasi S.H., Rezazadeh S.A. (2008) A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Prog Neuro-psychopharmacol Biol Psychiatr 32:1810-1815
8. Albuquerque EX, Alkondon M, Pereira E.F., Castro NG, Schrattenholz A, Barbosa CT, Bonfante-Cabarcas R, Aracava Y., Eisenberg HM, Maelicke A (1997) Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 280:1117-1136
9. Andreasson S, Allebeck P, Engstrom A., Rydberg U. (1987) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2:1483-1486
10. Arnt J, Bang-Andersen B, Grayson B., Bymaster FP, Cohen MP, DeLapp NW, Giethlen B, Kreilgaard M., McKinzie DL, Neill JC, Nelson DL, Nielsen SM, Poulsen MN, Schaus JM, Witten LM (2010) Lu AE58054, a 5-HT(6) antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol 13:1021-1033
11. Arseneault L, Cannon M, Poulton R., Murray R, Caspi A, Moffitt T.E. (2002) Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325:1212-1213
12. Babovic D, O'Tuathaigh CM, O'Connor AM, O'Sullivan GJ, Tighe O, Croke D.T., Karayiorgou M., Gogos JA, Cotter D, Waddington JL (2008) Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase. Neuroscience 155:1021-1029
13. Baker KB, Kim J.J. (2002) Effects of stress and hippocampal NMDA receptor antagonism on recognition memory in rats. Learn Mem 9:58-65
14. Ballaz SJ, Akil H, Watson S.J. (2007) The 5-HT7 receptor: role in novel object discrimination and relation to novelty-seeking behavior. Neuroscience 149:192-202
15. Barker GR, Bashir ZI, Brown M.W., Warburton E.C. (2006) A temporally distinct role for group I and group II metabotropic glutamate receptors in object recognition memory. Learn Mem 13:178-186
16. Barna I, Soproni K, Arszovszki A., Csabai K, Haller J. (2007) WIN-55,212-2 chronically implanted into the CA3 region of the dorsal hippocampus impairs learning: a novel method for studying chronic, brain-area-specific effects of cannabinoids. Behav Pharmacol 18:515-520
17. Barnett JH, Werners U, Secher S.M., Hill KE, Brazil R, Masson K, Pernet D.E., Kirkbride JB, Murray GK, Bullmore ET, Jones PB (2007) Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry 190:515-520
18. Bartko SJ, Winters BD, Cowell R.A., Saksida LM, Bussey T.J. (2007) Perceptual functions of perirhinal cortex in rats: zero-delay object recognition and simultaneous oddity discriminations. J Neurosci 27:2548-2559
19. Beaulieu JM, Gainetdinov R.R. (2011) The physiology, signaling and pharmacology of dopamine receptors. Pharmacol Rev 63:182-217
20. Belcher AM, Feinstein EM, O'Dell SJ, Marshall J.F. (2008) Metham-phetamine influences on recognition memory: comparison of escalating and single-day dosing regimens. Neuropsychopharma-cology 33:1453-1463
21. Bentley J, Marsden C, Sleight A., Fone K. (1999) Effect of the 5-HT6 antagonist, Ro 04-6790, on food consumption in rats trained to a fixed feeding regime. Br J Pharmacol: U38-U38
22. Bernstein HG, Grecksch G, Becker A., Hollt V, Bogerts B. (1999) Cellular changes in rat brain areas associated with neonatal hippocampal damage. Neuroreport 10:2307-2311
23. Bhardwaj SK, Baharnoori M, Sharif-Askari B, Kamath A., Williams S, Srivastava L.K. (2009) Behavioral characterization of dysbindin-1 deficient sandy mice. Behav Brain Res 197:435-441
24. Bianchi M, Fone KF, Azmi N, Heidbreder C.A., Hagan JJ, Marsden C.A. (2006) Isolation rearing induces recognition memory deficits accompanied by cytoskeletal alterations in rat hippocampus. Eur J Neurosci 24:2894-2902
25. Biton B, Bergis OE, Galli F, Nedelec A., Lochead AW, Jegham S, Godet D, Lanneau C., Santamaria R, Chesney F, Leonardon J, Granger P, Debono MW, Bohme GA, Sgard F, Besnard F, Graham D, Coste A, Oblin A, Curet O, Vige X, Voltz C, Rouquier L, Souilhac J, Santucci V, Gueudet C, Francon D, Steinberg R, Griebel G, Oury-Donat F, George P, Avenet P, Scatton B (2007) SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile. Neuropsychopharmacology 32:1-16
26. Boess FG, De Vry J, Erb C, Flessner T., Hendrix M, Luithle J, Methfessel C, Riedl B, Schnizler K, van der Staay FJ, van Kampen M, Wiese WB, Koenig G (2007) The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo [2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2- carboxa-mide improves working and recognition memory in rodents. J Pharmacol Exp Ther 321:716-725
27. Bortolozzi A, Diaz-Mataix L, Toth M., Celada P, Artigas F. (2007) In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl) 191:745-758
28. Botton PH, Costa MS, Ardais A.P., Mioranzza S., Souza DO, da Rocha JB, Porciuncula LO (2010) Caffeine prevents disruption of memory consolidation in the inhibitory avoidance and novel object recognition tasks by scopolamine in adult mice. Behav Brain Res 214:254-259
29. Boultadakis A, Liakos P, Pitsikas N. (2010) The nitric oxide-releasing derivative of ferulic acid NCX 2057 antagonized delay-dependent and scopolamine-induced performance deficits in a recognition memory task in the rat. Prog Neuropsychopharmacol Biol Psychiatr 34:5-9
30. Bradley SR, Lameh J, Ohrmund L., Son T, Bajpai A, Nguyen D., Friberg M, Burstein ES, Spalding TA, Ott TR, Schiffer HH, Tabatabaei A, McFarland K, Davis RE, Bonhaus DW (2010) AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. Neuropharmacology 58:365-373
31. Bromley E (2005) A collaborative approach to targeted treatment development for schizophrenia: a qualitative evaluation of the NIMH-MATRICS project. Schizophr Bull 31:954-961
32. Brown AS (2006) Prenatal infection as a risk factor for schizophrenia. Schizophr Bull 32:200-202
33. Brown MW, Bashir Z.I. (2002) Evidence concerning how neurons of the perirhinal cortex may effect familiarity discrimination. Philos Trans R Soc Lond B Biol Sci 357:1083-1095
34. Brown MW, Xiang J.Z. (1998) Recognition memory: neuronal substrates of the judgement of prior occurrence. Prog Neurobiol 55:149-189
35. Brown AS, Begg MD, Gravenstein S, Schaefer C.A., Wyatt RJ, Bresnahan M, Babulas VP, Susser E.S. (2004) Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 61:774-780
36. Buchanan RW, Summerfelt A, Tek C., Gold J. (2003) An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res 59:29-33
37. Buchanan RW, Conley RR, Dickinson D, Ball M.P., Feldman S., Gold JM, McMahon R.P. (2008) Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 165:82-89
38. Bussey TJ, Saksida L.M. (2005) Object memory and perception in the medial temporal lobe: an alternative approach. Curr Opin Neurobiol 15:730-737
39. Bussey TJ, Muir JL, Aggleton J.P. (1999) Functionally dissociating aspects of event memory: the effects of combined perirhinal and postrhinal cortex lesions on object and place memory in the rat. J Neurosci 19:495-502
40. Bussey TJ, Duck J, Muir J.L., Aggleton J.P. (2000) Distinct patterns of behavioural impairments resulting from fornix transection or neurotoxic lesions of the perirhinal and postrhinal cortices in the rat. Behav Brain Res 111:187-202
41. Bussey TJ, Holmes A, Lyon L., Mar AC, McAllister KA, Nithianantharajah J, Oomen C.A., Saksida L.M. (2011) New translational assays for preclinical modelling of cognition in schizophrenia: the touchscreen testing method for mice and rats. Neuropharmacology [Epub ahead of print].
42. Byrne M, Agerbo E, Bennedsen B., Eaton WW, Mortensen P.B. (2007) Obstetric conditions and risk of first admission with schizophrenia: a Danish national register based study. Schizophr Res 97:51-59
43. Calkins ME, Gur RC, Ragland J.D., Gur R.E. (2005) Face recognition memory deficits and visual object memory performance in patients with schizophrenia and their relatives. Am J Psychiatry 162:1963-1966
44. Camarasa J, Rodrigo T, Pubill D., Escubedo E. (2010) Memantine is a useful drug to prevent the spatial and non-spatial memory deficits induced by methamphetamine in rats. Pharmacol Res 62:450-456
45. Carli M, Bonalumi P, Samanin R. (1997) WAY 100635, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal administration of scopolamine or 7-chloro-kynurenic acid. Brain Res 774:167-174
46. Carlsson A, Lindqvist M. (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normeta-nephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 20:140-144
47. Chan MH, Chiu PH, Sou J.H., Chen H.H. (2008) Attenuation of ketamine-evoked behavioral responses by mGluR5 positive modulators in mice. Psychopharmacology (Berl) 198:141-148
48. Chiu CQ, Puente N, Grandes P., Castillo P.E. (2010) Dopaminergic modulation of endocannabinoid-mediated plasticity at GABAergic synapses in the prefrontal cortex. J Neurosci 30:7236-7248
49. Chung YC, Lee CR, Park T.W., Yang KH, Kim K.W. (2009) Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial. World J Biol Psychiatry 10:156-162
50. Clancy B, Darlington RB, Finlay B.L. (2001) Translating developmental time across mammalian species. Neuroscience 105:7-17
51. Clark RE, Zola SM, Squire L.R. (2000) Impaired recognition memory in rats after damage to the hippocampus. J Neurosci 20:8853-8860
52. Clark RE, Kuczenski R, Segal D.S. (2007) Escalating dose, multiple binge methamphetamine regimen does not impair recognition memory in rats. Synapse 61:515-522
53. Clarke JR, Rossato JI, Monteiro S, Bevilaqua L.R., Izquierdo I., Cammarota M. (2008) Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem 90:374-381
54. Cowell RA, Bussey TJ, Saksida L.M. (2006) Why does brain damage impair memory? A connectionist model of object recognition memory in perirhinal cortex. J Neurosci 26:12186-12197
55. Coyle JT (2006) Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26:365-384
56. Coyle P, Tran N, Fung J.N., Summers BL, Rofe A.M. (2009) Maternal dietary zinc supplementation prevents aberrant behaviour in an object recognition task in mice offspring exposed to LPS in early pregnancy. Behav Brain Res 197:210-218
57. Crabbe JC, Wahlsten D, Dudek B.C. (1999) Genetics of mouse behavior: interactions with laboratory environment. Science 284:1670-1672
58. Creese I, Burt DR, Snyder S.H. (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizo-phrenic drugs. Science 192:481-483
59. Dalman C, Thomas HV, David A.S., Gentz J., Lewis G, Allebeck P. (2001) Signs of asphyxia at birth and risk of schizophrenia. Population-based case-control study. Br J Psychiatry 179:403-408
60. Damgaard T, Larsen DB, Hansen S.L., Grayson B., Neill JC, Plath N. (2010) Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats. Behav Brain Res 207:144-150
61. Damgaard T, Plath N, Neill J.C., Hansen S.L. (2011) Extrasynaptic GABAA receptor activation reverses recognition memory deficits in an animal model of schizophrenia. Psychopharmacology (Berl) 214:403-413
62. Danion JM, Huron C, Vidailhet P., Berna F. (2007) Functional mechanisms of episodic memory impairment in schizophrenia. Can J Psychiatr 52:693-701
63. Davis KL, Kahn RS, Ko G, Davidson M. (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148:1474-1486
64. Dawson LA, Li P. (2003) Effects of 5-HT(6) receptor blockade on the neurochemical outcome of antidepressant treatment in the frontal cortex of the rat. J Neural Transm 110:577-590
65. Dawson LA, Nguyen HQ, Li P. (2000) In vivo effects of the 5-HT(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate. Br J Pharmacol 130:23-26
66. Dawson LA, Nguyen HQ, Li P. (2001) The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuro-psychopharmacology 25:662-668
67. de Bruin N., Pouzet B. (2006) Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval. Pharmacol Biochem Behav 85:253-260
68. de Leon J., Diaz F.J. (2005) A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 76:135-157
69. de Lima M.N., Laranja DC, Bromberg E, Roesler R., Schröder N (2005) Preor post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats. Behav Brain Res 156:139-143
70. Depatie L, O'Driscoll GA, Holahan AL, Atkinson V, Thavun-dayil JX, Kin N.N., Lal S. (2002) Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study. Neuropsychopharmacology 27: 1056-1070
71. Dere E, Huston JP, De Souza Silva MA (2007) The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev 31:673-704
72. Devito LM, Balu DT, Kanter B.R., Lykken C., Basu AC, Coyle JT, Eichenbaum H. (2010) Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology. Genes Brain Behav 10:210-222
73. Dewachter I, Ris L, Jaworski T., Seymour CM, Kremer A, Borghgraef P, De Vijver H, Godaux E, Van Leuven F (2009) GSK3β, a centre-staged kinase in neuropsychiatric disorders, modulates long term memory by inhibitory phosphorylation at serine-9. Neurobiol Dis 35:193-200
74. Diaz-Mataix L., Scorza MC, Bortolozzi A, Toth M., Celada P, Artigas F. (2005) Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 25:10831-10843
75. Dijk SN, Francis PT, Stratmann G.C., Bowen D.M. (1995) NMDA-induced glutamate and aspartate release from rat cortical pyramidal neurones: evidence for modulation by a 5-HT1A antagonist. Br J Pharmacol 115:1169-1174
76. Dixon L, Haas G, Weiden P.J., Sweeney J., Frances A.J. (1991) Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 148:224-230
77. Doleviczenyi Z, Vizi ES, Gacsalyi I, Pallagi K., Volk B, Harsing LG Jr, Halmos G, Lendvai B, Zelles T (2008) 5-HT6/7 receptor antagonists facilitate dopamine release in the cochlea via a GABAergic disinhibitory mechanism. Neurochem Res 33:2364-2372
78. Doniger GM, Foxe JJ, Murray M.M., Higgins BA, Javitt D.C. (2002) Impaired visual object recognition and dorsal/ventral stream interaction in schizophrenia. Arch Gen Psychiatry 59:1011-1020
79. Duffy L, Cappas E, Lai D., Boucher AA, Karl T. (2010) Cognition in transmembrane domain neuregulin 1 mutant mice. Neuroscience 170:800-807
80. Dyer MA, Freudenreich O, Culhane M.A., Pachas GN, Deckersbach T, Murphy E, Goff D.C., Evins A.E. (2008) High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr Res 102:88-95
81. Eacott MJ, Easton A, Zinkivskav A. (2005) Recollection in an episodic-like memory task in the rat. Learn Mem 12:221-223
82. Ebstein RP, Novick O, Umansky R., Priel B, Osher Y, Blaine D., Bennett ER, Nemanov L, Katz M, Belmaker RH (1996) Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking. Nat Genet 12:78-80
83. Ehrlichman RS, Luminais SN, White S.L., Rudnick ND, Ma N, Dow HC, Kreibich A.S., Abel T., Brodkin ES, Hahn CG, Siegel SJ (2009) Neuregulin 1 transgenic mice display reduced mismatch negativity, contextual fear conditioning and social interactions. Brain Res 1294:116-127
84. Ennaceur A, Delacour J. (1988) A new one-trial test for neurobiolog-ical studies of memory in rats. 1: Behavioral data. Behav Brain Res 31:47-59
85. Ennaceur A, Neave N, Aggleton J.P. (1996) Neurotoxic lesions of the perirhinal cortex do not mimic the behavioural effects of fornix transection in the rat. Behav Brain Res 80:9-25
86. Ennaceur A, Neave N, Aggleton J.P. (1997) Spontaneous object recognition and object location memory in rats: the effects of lesions in the cingulate cortices, the medial prefrontal cortex, the cingulum bundle and the fornix. Exp Brain Res 113:509-519
87. Fagerlund B, Soholm B, Fink-Jensen A, Lublin H., Glenthoj B.Y. (2007) Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. Clin Neuropharmacol 30:3-12
88. Forwood SE, Winters BD, Bussey T.J. (2005) Hippocampal lesions that abolish spatial maze performance spare object recognition memory at delays of up to 48 hours. Hippocampus 15:347-355
89. Franberg O, Marcus MM, Ivanov V, Schilstrom B., Shahid M, Svensson T.H. (2009) Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology (Berl) 204:251-264
90. Freedman R, Leonard S. (2001) Genetic linkage to schizophrenia at chromosome 15q14. Am J Med Genet 105:655-657
91. Freedman R, Hall M, Adler L.E., Leonard S. (1995) Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38:22-33
92. Freedman R, Leonard S, Gault J.M., Hopkins J., Cloninger CR, Kaufmann CA, Tsuang MT, Farone S.V., Malaspina D., Svrakic DM, Sanders A, Gejman P (2001) Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha7-nicotinic acetylcholine receptor subunit gene (CHRNA7). Am J Med Genet 105:20-22
93. Freedman R, Olincy A, Buchanan R.W., Harris JG, Gold JM, Johnson L, Allensworth D., Guzman-Bonilla A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F, Kem WR (2008) Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165:1040-1047
94. Freudenreich O, Herz L, Deckersbach T., Evins AE, Henderson DC, Cather C, Goff D.C. (2005) Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl) 181:358-363
95. Friedman JI, Adler DN, Howanitz E, Harvey P.D., Brenner G., Temporini H, White L, Parrella M., Davis K.L. (2002) A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 51:349-357
96. Friston KJ, Liddle PF, Frith C.D., Hirsch SR, Frackowiak R.S. (1992) The left medial temporal region and schizophrenia. A PET study. Brain 115(Pt 2):367-382
97. Gaffan D (1974) Recognition impaired and association intact in the memory of monkeys after transection of the fornix. J Comp Physiol Psychol 86:1100-1109
98. Gardiner JM (1988) Recognition failures and free-recall failures: implications for the relation between recall and recognition. Mem Cognit 16:446-451
99. Goff DC, Herz L, Posever T., Shih V, Tsai G, Henderson D.C., Freudenreich O., Evins AE, Yovel I, Zhang H, Schoenfeld D (2005) A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) 179:144-150
100. Goldman-Rakic PS (1994) Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci 6:348-357
101. Grayson B, Idris NF, Neill J.C. (2007) Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res 184:31-38
102. Green MF (2006) Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatr 67:e12
103. Greene R (2001) Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus 11:569-577
104. Grunze HC, Rainnie DG, Hasselmo M.E., Barkai E., Hearn EF, McCarley RW, Greene R.W. (1996) NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 16:2034-2043
105. Guo Y, Zhang H, Chen X., Cai W, Cheng J, Yang Y., Jin G, Zhen X (2009) Evaluation of the antipsychotic effect of bi-acetylated l-stepholidine (l-SPD-A), a novel dopamine and serotonin receptor dual ligand. Schizophr Res 115:41-49
106. Hannesson DK, Vacca G, Howland J.G., Phillips A.G. (2004) Medial prefrontal cortex is involved in spatial temporal order memory but not spatial recognition memory in tests relying on spontaneous exploration in rats. Behav Brain Res 153:273-285
107. Harris JG, Kongs S, Allensworth D., Martin L, Tregellas J, Sullivan B., Zerbe G, Freedman R (2004) Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 29:1378-1385
108. Harrison PJ, Weinberger D.R. (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatr 10:40-68, image 5
109. Harvey PD, Moriarty PJ, Friedman J.I., White L., Parrella M, Mohs RC, Davis K.L. (2000) Differential preservation of cognitive functions in geriatric patients with lifelong chronic schizophrenia: less impairment in reading compared with other skill areas. Biol Psychiatry 47:962-968
110. Hashimoto K, Fujita Y, Shimizu E., Iyo M. (2005) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur J Pharmacol 519:114-117
111. Hashimoto K, Ishima T, Fujita Y., Matsuo M, Kobashi T, Takahagi M., Tsukada H, Iyo M (2008) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711. Biol Psychiatry 63:92-97
112. Hauser TA, Kucinski A, Jordan K.G., Gatto GJ, Wersinger SR, Hesse RA, Stachowiak E.K., Stachowiak MK, Papke RL, Lippiello PM, Bencherif M (2009) TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem Pharmacol 78:803-812
113. Haydar SN, Yun H, Andrae P.M., Mattes J., Zhang J, Kramer A, Smith D.L., Huselton C., Graf R, Aschmies S, Schechter LE, Comery TA, Robichaud AJ (2010) 5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists. J Med Chem 53:2521-2527
114. Heckers S, Rauch SL, Goff D, Savage C.R., Schacter DL, Fischman AJ, Alpert N.M. (1998) Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat Neurosci 1:318-323
115. Heckers S, Curran T, Goff D., Rauch SL, Fischman AJ, Alpert NM, Schacter D.L. (2000) Abnormalities in the thalamus and prefrontal cortex during episodic object recognition in schizophrenia. Biol Psychiatry 48:651-657
116. Herring NR, Schaefer TL, Gudelsky G.A., Vorhees CV, Williams M.T. (2008) Effect of +-methamphetamine on path integration learning, novel object recognition, and neurotoxicity in rats. Psychopharmacology (Berl) 199:637-650
117. Hersi AI, Richard JW, Gaudreau P, Quirion R. (1995) Local modulation of hippocampal acetylcholine release by dopamine D1 receptors: a combined receptor autoradiography and in vivo dialysis study. J Neurosci 15:7150-7157
118. Higuera-Matas A., Botreau F, Miguens M., Del Olmo N, Borcel E, Perez-Alvarez L, Garcia-Lecumberri C, Ambrosio E (2009) Chronic periadolescent cannabinoid treatment enhances adult hippocampal PSA-NCAM expression in male Wistar rats but only has marginal effects on anxiety, learning and memory. Pharmacol Biochem Behav 93:482-490
119. Hirst WD, Stean TO, Rogers D.C., Sunter D., Pugh P, Moss SF, Bromidge S.M., Riley G., Smith DR, Bartlett S, Heidbreder CA, Atkins AR, Lacroix LP, Dawson LA, Foley AG, Regan CM, Upton N (2006) SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol 553:109-119
120. Hirst WD, Andree TH, Aschmies S, Childers W.E., Comery TA, Dawson LA, Day M, Feingold I.B., Grauer SM, Harrison BL, Hughes ZA, Kao J, Kelly MG, van der Lee H, Rosenzweig-Lipson S, Saab AL, Smith DL, Sullivan K, Rizzo SJ, Tio C, Zhang MY, Schechter LE (2008) Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexan e carboxamide (WAY-101405). J Pharmacol Exp Ther 325:134-145
121. Hong LE, Schroeder M, Ross T.J., Buchholz B., Salmeron BJ, Wonodi I, Thaker GK, Stein E.A. (2011) Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia. Schizophr Bull 37:416-425
122. Hori SE, Powell KJ, Robertson G.S. (2007) Darbepoetin alfa (Aranesp) improves recognition memory in adult rats that have sustained bilateral ventral hippocampal lesions as neonates or young adults. Neuroscience 144:1-7
123. Hu JH, Ma YH, Jiang J, Yang N., Duan SH, Jiang ZH, Mei ZT, Fei J, Guo L.H. (2004) Cognitive impairment in mice over-expressing gamma-aminobutyric acid transporter 1 (GAT1). Neuroreport 15:9-12
124. Huang M, Li Z, Dai J., Shahid M, Wong EH, Meltzer H.Y. (2008) Asenapine increases dopamine, norepinephrine, and acetylcho-line efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacology 33:2934-2945
125. Hultman CM, Sparen P, Takei N., Murray RM, Cnattingius S. (1999) Prenatal and perinatal risk factors for schizophrenia, affective psychosis, and reactive psychosis of early onset: case-control study. BMJ 318:421-426
126. Ibi D, Nagai T, Koike H., Kitahara Y, Mizoguchi H, Niwa M., Jaaro-Peled H, Nitta A, Yoneda Y, Nabeshima T, Sawa A, Yamada K (2010) Combined effect of neonatal immune activation and mutant DISC1 on phenotypic changes in adulthood. Behav Brain Res 206:32-37
127. Ichikawa J, Li Z, Dai J., Meltzer H.Y. (2002) Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 956:349-357
128. Ito HT, Smith SE, Hsiao E, Patterson P.H. (2010) Maternal immune activation alters nonspatial information processing in the hippocampus of the adult offspring. Brain Behav Immun 24:930-941
129. Jackson ME, Homayoun H, Moghaddam B. (2004) NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci USA 101:8467-8472
130. Javitt DC (2009) Sensory processing in schizophrenia: neither simple nor intact. Schizophr Bull 35:1059-1064
131. Jenkins TA, Harte MK, Stenson G, Reynolds G.P. (2009) Neonatal lipopolysaccharide induces pathological changes in parvalbumin immunoreactivity in the hippocampus of the rat. Behav Brain Res 205:355-359
132. Johnson DJ, Forbes IT, Watson S.P., Garzya V., Stevenson GI, Walker GR, Mudhar HS, Flynn S.T., Wyman PA, Smith PW, Murkitt GS, Lucas AJ, Mookherjee CR, Watson JM, Gartlon JE, Bradford AM, Brown F (2010) The discovery of a series of N-substituted 3-(4-piperidinyl)-1,3-benzoxazolinones and oxindoles as highly brain penetrant, selective muscarinic M1 agonists. Bioorg Med Chem Lett 20:5434-5438
133. Jones DN, Higgins G.A. (1995) Effect of scopolamine on visual attention in rats. Psychopharmacology (Berl) 120:142-149
134. Jones CA, Brown AM, Auer D.P., Fone K.C. (2010) The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat. Psychopharmacology (Berl) 214:269-283
135. Kalechstein AD, Newton TF, Green M. (2003) Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J Neuropsychiatry Clin Neurosci 15:215-220
136. Kamei H, Nagai T, Nakano H., Togan Y, Takayanagi M, Takahashi K., Kobayashi K, Yoshida S, Maeda K, Takuma K, Nabeshima T, Yamada K (2006) Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice. Biol Psychiatry 59:75-84
137. Kapur S, Remington G. (2001) Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 50:873-883
138. Karasawa J, Hashimoto K, Chaki S. (2008) D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res 186:78-83
139. Keefe RS, Bilder RM, Davis S.M., Harvey PD, Palmer BW, Gold JM, Meltzer H.Y., Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64:633-647
140. Keefe RS, Malhotra AK, Meltzer H.Y., Kane JM, Buchanan RW, Murthy A, Sovel M., Li C, Goldman R (2008) Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsy-chopharmacology 33:1217-1228
141. Kendall I, Slotten HA, Codony X, Burgueno J., Pauwels PJ, Vela JM, Fone K.C. (2011) E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. Psychopharmacology (Berl) 213:413-430
142. King MV, Sleight AJ, Woolley M.L., Topham IA, Marsden CA, Fone K.C. (2004) 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation-an effect sensitive to NMDA receptor antagonism. Neuropharmacology 47:195-204
143. King MV, Spicer CH, Sleight A.J., Marsden CA, Fone K.C. (2009) Impact of regional 5-HT depletion on the cognitive enhancing effects of a typical 5-ht(6) receptor antagonist, Ro 04-6790, in the Novel Object Discrimination task. Psychopharmacology (Berl) 202:111-123
144. Krivoy A, Weizman A, Laor L., Hellinger N, Zemishlany Z, Fischel T. (2008) Addition of memantine to antipsychotic treatment in schizophrenia
145. Krystal JH, Karper LP, Seibyl J.P., Freeman GK, Delaney R, Bremner JD, Heninger G.R., Bowers MB, Charney DS (1994) Subanes-thetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214
146. Krystal JH, D'Souza DC, Madonick S, Petrakis I.L. (1999) Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophr Res 35(Suppl):S35-S49
147. Kunitachi S, Fujita Y, Ishima T., Kohno M, Horio M, Tanibuchi Y., Shirayama Y, Iyo M, Hashimoto K (2009) Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors. Brain Res 1279:189-196
148. Lahti AC, Koffel B, LaPorte D., Tamminga C.A. (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuro-psychopharmacology 13:9-19
149. Lane HY, Huang CL, Wu P.L., Liu YC, Chang YC, Lin PY, Chen P.W., Tsai G. (2006) Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 60:645-649
150. Lane HY, Lin CH, Huang Y.J., Liao CH, Chang YC, Tsai G.E. (2010) A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol 13:451-460
151. Lee SW, Lee JG, Lee B.J., Kim Y.H. (2007) A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int Clin Psychopharmacol 22:63-68
152. Leonard S, Gault J, Moore T., Hopkins J, Robinson M, Olincy A., Adler LE, Cloninger CR, Kaufmann CA, Tsuang MT, Faraone SV, Malaspina D, Svrakic DM, Freedman R (1998) Further investigation of a chromosome 15 locus in schizophrenia: analysis of affected sibpairs from the NIMH Genetics Initiative. Am J Med Genet 81:308-312
153. Levin ED, Rezvani A.H. (2006) Nicotinic-antipsychotic drug interactions and cognitive function. EXS 98:185-205
154. Levin ED, Rose J.E. (1995) Acute and chronic nicotinic interactions with dopamine systems and working memory performance. Ann N Y Acad Sci 757:245-252
155. Levin ED, Simon B.B. (1998) Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl) 138:217-230
156. Levin ED, Wilson W, Rose J.E., McEvoy J. (1996) Nicotinehaloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 15:429-436
157. Levine S, Berkenbosch F, Suchecki D., Tilders F.J. (1994) Pituitary-adrenal and interleukin-6 responses to recombinant interleukin-1 in neonatal rats. Psychoneuroendocrinology 19:143-153
158. Lewis DA, Hashimoto T, Volk D.W. (2005) Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6:312-324
159. Li Z, Snigdha S, Roseman A.S., Dai J., Meltzer H.Y. (2008) Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine. Eur J Pharmacol 596:89-97
160. Lieben CK, Blokland A, Sik A., Sung E, van Nieuwenhuizen P, Schreiber R. (2005) The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat. Neuro-psychopharmacology 30:2169-2179
161. Lieberman JA, Papadakis K, Csernansky J., Litman R, Volavka J, Jia X.D., Gage A. (2009) A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 34:1322-1329
162. Lipska BK, Jaskiw GE, Weinberger D.R. (1993) Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology 9:67-75
163. Lipska BK, Aultman JM, Verma A, Weinberger D.R., Moghaddam B. (2002) Neonatal damage of the ventral hippocampus impairs working memory in the rat. Neuropsychopharmacology 27:47-54
164. Liu F, Grauer S, Kelley C., Navarra R, Graf R, Zhang G., Atkinson PJ, Popiolek M, Wantuch C, Khawaja X, Smith D, Olsen M, Kouranova E, Lai M, Pruthi F, Pulicicchio C, Day M, Gilbert A, Pausch MH, Brandon NJ, Beyer CE, Comery TA, Logue S, Rosenzweig-Lipson S, Marquis KL (2008) ADX47273 [S-(4-fluoro-phenyl)- {3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol Exp Ther 327:827-839
165. Long LE, Chesworth R, Arnold J.C., Karl T. (2010) A follow-up study: acute behavioural effects of Delta(9)-THC in female heterozygous neuregulin 1 transmembrane domain mutant mice. Psycho-pharmacology (Berl) 211:277-289
166. Lung FW, Shu BC, Kao W.T., Chen CN, Ku YC, Tzeng D.S. (2009) Association of DRD4 uVNTR and TP53 codon 72 polymorphisms with schizophrenia: a case-control study. BMC Med Genet 10:147
167. MacEwan GW, Ehmann TS, Khanbhai I, Wrixon C (2001) Donepezil in schizophrenia-is it helpful? An experimental design case study. Acta Psychiatr Scand 104:469-472
168. Macor JE, Gurley D, Lanthorn T., Loch J, Mack RA, Mullen G, Tran O., Wright N, Gordon JC (2001) The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist. Bioorg Med Chem Lett 11:319-321
169. Maia L, de Mendonca A (2002) Does caffeine intake protect from Alzheimer's disease? Eur J Neurol 9:377-382
170. Malaspina D, Harkavy-Friedman J, Corcoran C., Mujica-Parodi L, Printz D, Gorman J.M., Van Heertum R (2004) Resting neural activity distinguishes subgroups of schizophrenia patients. Biol Psychiatry 56:931-937
171. Manns JR, Stark CE, Squire L.R. (2000) The visual paired-comparison task as a measure of declarative memory. Proc Natl Acad Sci USA 97:12375-12379
172. Marcos B, Gil-Bea FJ, Hirst W.D., Garcia-Alloza M, Ramirez M.J. (2006) Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release. Eur J Neurosci 24:1299-1306
173. Marutle A, Zhang X, Court J., Piggott M, Johnson M, Perry R., Perry E, Nordberg A (2001) Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat 22:115-126
174. Massey PV, Bhabra G, Cho K., Brown MW, Bashir Z.I. (2001) Activation of muscarinic receptors induces protein synthesis-dependent long-lasting depression in the perirhinal cortex. Eur J Neurosci 14:145-152
175. Mattay VS, Goldberg TE, Fera F, Hariri A.R., Tessitore A., Egan MF, Kolachana B, Callicott JH, Weinberger D.R. (2003) Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 100:6186-6191
176. McCreary AC, Glennon JC, Ashby CR Jr, Meltzer HY, Li Z, Reinders JH, Hesselink M.B., Long SK, Herremans AH, van Stuivenberg H, Feenstra RW, Kruse CG (2007) SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)- pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug. Neuropsychopharmacology 32:78-94
177. McKee RD, Squire L.R. (1993) On the development of declarative memory. J Exp Psychol Learn Mem Cogn 19:397-404
178. McKibben CE, Jenkins TA, Adams H.N., Harte MK, Reynolds G.P. (2010) Effect of pretreatment with risperidone on phencyclidine-induced disruptions in object recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat. Behav Brain Res 208:132-136
179. McLean SL, Woolley ML, Thomas D, Neill J.C. (2009) Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat. Psychopharmacology (Berl) 206:403-414
180. McLean SL, Grayson B, Idris N.F., Lesage AS, Pemberton DJ, Mackie C, Neill J.C. (2011) Activation of alpha7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: implications for therapy of cognitive dysfunction in schizophrenia. Eur Neuropsychopharmacol 21:333-343
181. Messier C (1997) Object recognition in mice: improvement of memory by glucose. Neurobiol Learn Mem 67:172-175
182. Meyer U, Feldon J. (2010) Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog Neurobiol 90:285-326
183. Millan MJ, Mannoury la Cour C, Novi F, Maggio R, Audinot V, Newman-Tancredi A, Cussac D, Pasteau V, Boutin JA, Dubuffet T, Lavielle G (2008) S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c] pyrr ol-2(3H)-yl)-eth-yl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors. J Pharmacol Exp Ther 324:587-599
184. Millan MJ, Buccafusco JJ, Loiseau F, Watson D.J., Decamp E., Fone KC, Thomasson-Perret N, Hill M, Mocaer E., Schneider J.S. (2010) The dopamine D(3) receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. Int J Neuropsychopharmacol 13:1035-1051
185. Minzenberg MJ, Poole JH, Benton C, Vinogradov S. (2004) Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 161:116-124
186. Mishkin M, Delacour J. (1975) An analysis of short-term visual memory in the monkey. J Exp Psychol Anim Behav Process 1:326-334
187. Mitchell JB, Laiacona J (1998) The medial frontal cortex and temporal memory: tests using spontaneous exploratory behaviour in the rat. Behav Brain Res 97:107-113
188. Mitchell ES, Neumaier J.F. (2005) 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol Ther 108:320-333
189. Moghaddam B, Adams B.W. (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1349-1352
190. Moore TH, Zammit S, Lingford-Hughes A, Barnes T.R., Jones PB, Burke M, Lewis G. (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370:319-328
191. Morales P, Simola N, Bustamante D., Lisboa F, Fiedler J, Gebicke-Haerter PJ, Morelli M., Tasker RA, Herrera-Marschitz M (2010) Nicotinamide prevents the long-term effects of perinatal asphyxia on apoptosis, non-spatial working memory and anxiety in rats. Exp Brain Res 202:1-14
192. Mumby DG, Pinel JP, Wood E.R. (1990) Nonrecurring-items nonmatching-to-sample in rats: a new paradigm for testing non-spatial working memory. Psychobiology 18:321-326
193. Myers CS, Robles O, Kakoyannis A.N., Sherr JD, Avila MT, Blaxton TA, Thaker G.K. (2004) Nicotine improves delayed recognition in schizophrenic patients. Psychopharmacology (Berl) 174:334-340
194. Nagai T, Takuma K, Dohniwa M, Ibi D, Mizoguchi H, Kamei H, Nabeshima T, Yamada K (2007) Repeated methamphetamine treatment impairs spatial working memory in rats: reversal by clozapine but not haloperidol. Psychopharmacology (Berl) 194:21-32
195. Nagai T, Murai R, Matsui K., Kamei H, Noda Y, Furukawa H., Nabeshima T. (2009) Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl) 202:315-328
196. Nemanic S, Alvarado MC, Bachevalier J. (2004) The hippocampal/ parahippocampal regions and recognition memory: insights from visual paired comparison versus object-delayed nonmatching in monkeys. J Neurosci 24:2013-2026
197. Nilsson M, Hansson S, Carlsson A., Carlsson M.L. (2007) Differential effects of the N-methyl-d-aspartate receptor antagonist MK-801 on different stages of object recognition memory in mice. Neuroscience 149:123-130
198. Niwa M, Matsumoto Y, Mouri A., Ozaki N, Nabeshima T. (2011) Vulnerability in early life to changes in the rearing environment plays a crucial role in the aetiopathology of psychiatric disorders. Int J Neuropsychopharmacol 14:459-477
199. Noda Y, Mouri A, Ando Y., Waki Y, Yamada SN, Yoshimi A, Yamada K., Ozaki N, Wang D, Nabeshima T (2010) Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems. Int J Neuropsychopharmacol 13:1343-1354
200. Olincy A, Harris JG, Johnson L.L., Pender V., Kongs S, Allensworth D, Ellis J., Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63:630-638
201. O'Tuathaigh C.M., O'Sullivan GJ, Kinsella A, Harvey R.P., Tighe O., Croke DT, Waddington J.L. (2006) Sexually dimorphic changes in the exploratory and habituation profiles of heterozygous neuregulin-1 knockout mice. Neuroreport 17:79-83
202. O'Tuathaigh C.M., Hryniewiecka M, Behan A., Tighe O, Coughlan C, Desbonnet L., Cannon M, Karayiorgou M, Gogos JA, Cotter DR, Waddington JL (2010) Chronic adolescent exposure to Delta-9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes. Neuropsychopharmacol-ogy 35:2262-2273
203. Overman WH, Bachevalier J, Sewell F., Drew J. (1993) A comparison of children's performance on two recognition memory tasks: delayed nonmatch-to-sample versus visual paired-comparison. Dev Psychobiol 26:345-357
204. Owens DG, Johnstone E.C. (2006) Precursors and prodromata of schizophrenia: findings from the Edinburgh High Risk Study and their literature context. Psychol Med 36:1501-1514
205. Ozawa K, Hashimoto K, Kishimoto T., Shimizu E, Ishikura H, Iyo M. (2006) Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry 59:546-554
206. Papaleo F, Crawley JN, Song J, Lipska B.K., Pickel J., Weinberger DR, Chen J. (2008) Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J Neurosci 28:8709-8723
207. Pascalis O, Hunkin NM, Holdstock J.S., Isaac CL, Mayes A.R. (2004) Visual paired comparison performance is impaired in a patient with selective hippocampal lesions and relatively intact item recognition. Neuropsychologia 42:1293-1300
208. Patil ST, Zhang L, Martenyi F., Lowe SL, Jackson KA, Andreev BV, Avedisova A.S., Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13:1102-1107
209. Pelletier M, Achim AM, Montoya A, Lal S., Lepage M. (2005) Cognitive and clinical moderators of recognition memory in schizophrenia: a meta-analysis. Schizophr Res 74:233-252
210. Pereira LO, Strapasson AC, Nabinger P.M., Achaval M., Netto C.A. (2008) Early enriched housing results in partial recovery of memory deficits in female, but not in male, rats after neonatal hypoxia-ischemia. Brain Res 1218:257-266
211. Pichat P, Bergis OE, Terranova J.P., Urani A., Duarte C, Santucci V, Gueudet C., Voltz C, Steinberg R, Stemmelin J, Oury-Donat F, Avenet P, Griebel G, Scatton B (2007) SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 32:17-34
212. Pietá Dias C, Martins de Lima MN, Presti-Torres J, Dornelles A, Garcia VA, Siciliani Scalco F, Rewsaat Guimarães M, Constantino L, Budni P, Dal-Pizzol F, Schröder N (2007) Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats. Neuroscience 146:1719-1725
213. Pitsikas N, Rigamonti AE, Cella S.G., Muller E.E. (2003) The 5-HT 1A receptor antagonist WAY 100635 improves rats performance in different models of amnesia evaluated by the object recognition task. Brain Res 983:215-222
214. Prast H, Philippu A. (2001) Nitric oxide as modulator of neuronal function. Prog Neurobiol 64:51-68
215. Puma C, Bizot J.C. (1998) Intraseptal infusions of a low dose of AP5, a NMDA receptor antagonist, improves memory in an object recognition task in rats. Neurosci Lett 248:183-186
216. Quinn HR, Matsumoto I, Callaghan P.D., Long LE, Arnold JC, Gunasekaran N, Thompson M.R., Dawson B., Mallet PE, Kashem MA, Matsuda-Matsumoto H, Iwazaki T, McGregor IS (2008) Adolescent rats find repeated Delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 33:1113-1126
217. Radcliffe KA, Dani J.A. (1998) Nicotinic stimulation produces multiple forms of increased glutamatergic synaptic transmission. J Neurosci 18:7075-7083
218. Radyushkin K, El-Kordi A, Boretius S., Castaneda S, Ronnenberg A, Reim K., Bickeböller H, Frahm J, Brose N, Ehrenreich H (2010) Complexin2 null mutation requires a 'second hit' for induction of phenotypic changes relevant to schizophrenia. Genes Brain Behav 9:592-602
219. Raedler TJ, Bymaster FP, Tandon R, Copolov D., Dean B. (2007) Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatr 12:232-246
220. Rammsayer TH (2001) Effects of pharmacologically induced changes in NMDA-receptor activity on long-term memory in humans. Learn Mem 8:20-25
221. Rasmusson DD (2000) The role of acetylcholine in cortical synaptic plasticity. Behav Brain Res 115:205-218
222. Reichel CM, Schwendt M, McGinty J.F., Foster Olive M, See R.E. (2011) Loss of object recognition memory produced by extended access to methamphetamine self-administration is reversed by positive allosteric modulation of metabotropic glutamate receptor 5. Neuropsychopharmacology 36:782-792
223. Riedel W, Hogervorst E, Leboux R., Verhey F, van Praag H, Jolles J. (1995) Caffeine attenuates scopolamine-induced memory impairment in humans. Psychopharmacology (Berl) 122:158-168
224. Riemer C, Borroni E, Levet-Trafit B, Martin J.R., Poli S., Porter RH, Bos M. (2003) Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1- ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J Med Chem 46:1273-1276
225. Riley BP, Makoff A, Mogudi-Carter M, Jenkins T., Williamson R, Collier D, Murray R. (2000) Haplotype transmission disequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in Southern African Bantu families. Am J Med Genet 96:196-201
226. Risch SC, McGurk S, Horner M.D., Nahas Z., Owens SD, Molloy M, Gilliard C, Christie S., Markowitz JS, DeVane CL, Mintzer J, George MS (2001) A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. Neurocase 7:105-110
227. Ritchie K, Carriere I, de Mendonca A, Portet F, Dartigues J.F., Rouaud O., Barberger-Gateau P, Ancelin ML (2007) The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology 69:536-545
228. Robbins TW (2005) Synthesizing schizophrenia: a bottom-up, symptomatic approach. Schizophr Bull 31:854-864
229. Rollema H, Lu Y, Schmidt A.W., Zorn S.H. (1997) Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol 338:R3-R5
230. Roncarati R, Scali C, Comery T.A., Grauer SM, Aschmi S, Bothmann H, Jow B., Kowal D, Gianfriddo M, Kelley C, Zanelli U, Ghiron C, Haydar S, Dunlop J, Terstappen GC (2009) Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. J Pharmacol Exp Ther 329:459-468
231. Rothblat LA, Hayes L.L. (1987) Short-term object recognition memory in the rat: nonmatching with trial-unique junk stimuli. Behav Neurosci 101:587-590
232. Sambeth A, Riedel WJ, Smits L.T., Blokland A. (2007) Cholinergic drugs affect novel object recognition in rats: relation with hippocampal EEG? Eur J Pharmacol 572:151-159
233. Sams-Dodd F., Lipska BK, Weinberger D.R. (1997) Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology (Berl) 132:303-310
234. Sarter M, Bruno J.P. (1997) Trans-synaptic stimulation of cortical acetylcholine and enhancement of attentional functions: a rational approach for the development of cognition enhancers. Behav Brain Res 83:7-14
235. Schiapparelli L, Simon AM, Del Rio J, Frechilla D. (2006) Opposing effects of AMPA and 5-HT1A receptor blockade on passive avoidance and object recognition performance: correlation with AMPA receptor subunit expression in rat hippocampus. Neuro-pharmacology 50:897-907
236. Schneider M, Koch M. (2003) Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28:1760-1769
237. Schreiber R, Vivian J, Hedley L., Szczepanski K, Secchi RL, Zuzow M, van Laarhoven S, Moreau JL, Martin JR, Sik A, Blokland A (2007) Effects of the novel 5-HT(6) receptor antagonist RO4368554 in rat models for cognition and sensorimotor gating. Eur Neuropsychopharmacol 17:277-288
238. Schroder N, O'Dell SJ, Marshall J.F. (2003) Neurotoxic methamphet-amine regimen severely impairs recognition memory in rats. Synapse 49:89-96
239. Schubert MH, Young KA, Hicks P.B. (2006) Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry 60:530-533
240. Scott JC, Woods SP, Matt G.E., Meyer RA, Heaton RK, Atkinson JH, Grant I. (2007) Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 17:275-297
241. Scoville WB, Milner B. (1957) Loss of recent memory after bilateral hippocampal lesions. J Neurol Neurosurg Psychiatry 20:11-21
242. Seeman P, Lee T. (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188:1217-1219
243. Seeman P, Guan HC, Van Tol HH (1993) Dopamine D4 receptors elevated in schizophrenia. Nature 365:441-445
244. Seidman LJ, Lanca M, Kremen W.S., Faraone SV, Tsuang M.T. (2003) Organizational and visual memory deficits in schizophrenia and bipolar psychoses using the Rey-Osterrieth complex figure: effects of duration of illness. J Clin Exp Neuropsychol 25:949-964
245. Shiina A, Shirayama Y, Niitsu T., Hashimoto T, Yoshida T, Hasegawa T., Haraguchi T, Kanahara N, Shiraishi T, Fujisaki M, Fukami G, Nakazato M, Iyo M, Hashimoto K (2010) A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann Gen Psychiatr 9:27
246. Shirayama Y, Yamamoto A, Nishimura T., Katayama S, Kawahara R. (2007) Subsequent exposure to the choline uptake enhancer MKC-231 antagonizes phencyclidine-induced behavioral deficits and reduction in septal cholinergic neurons in rats. Eur Neuropsychopharmacol 17:616-626
247. Shirazi-Southall S., Rodriguez DE, Nomikos G.G. (2002) Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26:583-594
248. Simola N, Bustamante D, Pinna A., Pontis S, Morales P, Morelli M., Herrera-Marschitz M (2008) Acute perinatal asphyxia impairs non-spatial memory and alters motor coordination in adult male rats. Exp Brain Res 185:595-601
249. Singer P, Boison D, Möhler H, Feldon J., Yee B.K. (2007) Enhanced recognition memory following glycine transporter 1 deletion in forebrain neurons. Behav Neurosci 121:815-825
250. Singer JM, Wilson MW, Johnson P.D., Graham SR, Cooke LW, Roof RL, Boxer P.A., Gold LH, Meltzer LT, Janssen A, Roush N, Campbell JE, Su TZ, Hurst SI, Stoner CL, Schwarz JB (2009) Synthesis and SAR of tolylamine 5-HT6 antagonists. Bioorg Med Chem Lett 19:2409-2412
251. Smith RC, Warner-Cohen J, Matute M., Butler E, Kelly E, Vaidhyanathaswamy S., Khan A. (2006) Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology 31:637-643
252. Smith RC, Lindenmayer JP, Davis J.M., Cornwell J., Noth K, Gupta S, Sershen H., Lajtha A. (2009a) Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res 110:149-155
253. Smith SM, Uslaner JM, Yao L, Mullins C.M., Surles NO, Huszar SL, McNaughton CH, Pascarella D.M., Kandebo M., Hinchliffe RM, Sparey T, Brandon NJ, Jones B, Venkatraman S, Young MB, Sachs N, Jacobson MA, Hutson P.H. (2009b) The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine. J Pharmacol Exp Ther 328:921-930
254. Snigdha S, Idris N, Grayson B., Shahid M, Neill J.C. (2010) Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D(1) receptor mechanism. Psychopharmacology (Berl) 214:843-853
255. Sood P, Idris NF, Cole S, Grayson B., Neill JC, Young A.M. (2010) PD168077, a D4 receptor agonist, reverses object recognition deficits in rats: potential role for D4 receptor mechanisms in improving cognitive dysfunction in schizophrenia. J Psychophar-macol 25:792-800
256. Steckler T, Sahgal A. (1995) The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour. Behav Brain Res 67:165-199
257. Stober G, Saar K, Ruschendorf F., Meyer J, Nurnberg G, Jatzke S., Franzek E, Reis A, Lesch KP, Wienker TF, Beckmann H (2000) Splitting schizophrenia: periodic catatonia-susceptibility locus on chromosome 15q15. Am J Hum Genet 67:1201-1207
258. Sullivan EV, Mathalon DH, Ha C.N., Zipursky RB, Pfefferbaum A. (1992) The contribution of constructional accuracy and organizational strategy to nonverbal recall in schizophrenia and chronic alcoholism. Biol Psychiatry 32:312-333
259. Sullivan PF, Kendler KS, Neale M.C. (2003) Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 60:1187-1192
260. Sydserff S, Sutton EJ, Song D, Quirk M.C., Maciag C., Li C, Jonak G, Gurley D., Gordon JC, Christian EP, Doherty JJ, Hudzik T, Johnson E, MrzljakL, Piser T, Smagin GN, WangY, Widzowski D, Smith JS (2009) Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. Biochem Pharmacol 78:880-888
261. Taylor SB, Markham JA, Taylor A.R., Kanaskie BZ, Koenig J.I. (2011) Sex-specific neuroendocrine and behavioral phenotypes in hypo-morphic Type II Neuregulin 1 rats. Behav Brain Res 224:223-232
262. Tordera RM, Totterdell S, Wojcik S.M., Brose N., Elizalde N, Lasheras B, Del Rio J (2007) Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1). Eur J Neurosci 25:281-290
263. Tretter V, Revilla-Sanchez R, Houston C., Terunuma M, Havekes R, Florian C., Jurd R, Vithlani M, Michels G, Couve A, Sieghart W, Brandon N, Abel T, Smart TG, Moss SJ (2009) Deficits in spatial memory correlate with modified {gamma}-aminobutyric acid type A receptor tyrosine phosphorylation in the hippocampus. Proc Natl Acad Sci USA 106:20039-20044
264. Tsai G, Yang P, Chung L.C., Lange N., Coyle J.T. (1998) D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44:1081-1089
265. Tugal O, Yazici KM, Anil Yagcioglu AE, Gogus A. (2004) A doubleblind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsycho-pharmacol 7:117-123
266. Tulving E (1985) How many memory systems are there? Am Psychol 40:385-398
267. Uslaner JM, Parmentier-Batteur S, Flick R.B., Surles NO, Lam JS, McNaughton CH, Jacobson M.A., Hutson P.H. (2009) Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus. Neuropharmacology 57:531-538
268. van der Stelt M, Di Marzo V (2003) The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 480:133-150
269. Van Dort C.J., Baghdoyan HA, Lydic R. (2009) Adenosine A(1) and A (2A) receptors in mouse prefrontal cortex modulate acetylcholine release and behavioral arousal. J Neurosci 29:871-881
270. Vigano D, Guidali C, Petrosino S., Realini N, Rubino T, Di Marzo V, Parolaro D (2009) Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. Int J Neuropsychopharmacol 12:599-614
271. Vijayraghavan S, Wang M, Birnbaum S.G., Williams GV, Arnsten A.F. (2007) Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci 10:376-384
272. Wallace TL, Callahan PM, Tehim A, Bertrand D., Tombaugh G, Wang S, Xie W., Rowe WB, Ong V, Graham E, Terry AV Jr, Rodefer JS, Herbert B, Murray M, Porter R, Santarelli L, Lowe DA (2011) RG3487, a novel nicotinic alpha7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J Pharmacol Exp Ther 336:242-253
273. Warburton EC, Koder T, Cho K., Massey PV, Duguid G, Barker GR, Aggleton J.P., Bashir ZI, Brown MW (2003) Cholinergic neurotransmission is essential for perirhinal cortical plasticity and recognition memory. Neuron 38:987-996
274. Weiser M, Reichenberg A, Grotto I., Yasvitzky R, Rabinowitz J, Lubin G., Nahon D, Knobler HY, Davidson M (2004) Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. Am J Psychiatry 161:1219-1223
275. West PJ, Marcy VR, Marino M.J., Schaffhauser H. (2009) Activation of the 5-HT(6) receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus. Neuroscience 164:692-701
276. Winters BD, Bussey T.J. (2005a) Glutamate receptors in perirhinal cortex mediate encoding, retrieval, and consolidation of object recognition memory. J Neurosci 25:4243-4251
277. Winters BD, Bussey T.J. (2005b) Removal of cholinergic input to perirhinal cortex disrupts object recognition but not spatial working memory in the rat. Eur J Neurosci 21:2263-2270
278. Winters BD, Forwood SE, Cowell R.A., Saksida LM, Bussey T.J. (2004) Double dissociation between the effects of peri-postrhinal cortex and hippocampal lesions on tests of object recognition and spatial memory: heterogeneity of function within the temporal lobe. J Neurosci 24:5901-5908
279. Winters BD, Saksida LM, Bussey T.J. (2006) Paradoxical facilitation of object recognition memory after infusion of scopolamine into perirhinal cortex: implications for cholinergic system function. J Neurosci 26:9520-9529
280. Winters BD, Saksida LM, Bussey T.J. (2008) Object recognition memory: neurobiological mechanisms of encoding, consolidation and retrieval. Neurosci Biobehav Rev 32:1055-1070
281. Winters BD, Bartko SJ, Saksida L.M., Bussey T.J. (2010) Muscimol, AP5, or scopolamine infused into perirhinal cortex impairs two-choice visual discrimination learning in rats. Neurobiol Learn Mem 93:221-228
282. Wishka DG, Walker DP, Yates K.M., Reitz SC, Jia S, Myers JK, Olson K.L., Jacobsen EJ, Wolfe ML, Groppi VE, Hanchar AJ, Thornburgh BA, Cortes-Burgos LA, Wong EH, Staton BA, Raub TJ, Higdon NR, Wall TM, Hurst RS, Walters RR, Hoffmann WE, Hajos M, Franklin S, Carey G, Gold LH, Cook KK, Sands SB, Zhao SX, Soglia JR, Kalgutkar AS, Arneric SP, Rogers BN (2006) Discovery of N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure-activity relationship. J Med Chem 49:4425-4436
283. Woo TU, Miller JL, Lewis D.A. (1997) Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. Am J Psychiatry 154:1013-1015
284. Woolley M, Marsden C, Sleight A., Fone K. (2000) Reversal of a scopolamine-induced deficit in object discrimination by a selective 5-HT6 receptor antagonist, Ro 046790, in rats. Br J Pharmacol: U39-U39.
285. Woolley ML, Marsden CA, Sleight A.J., Fone K.C. (2003) Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790. Psychopharmacology (Berl) 170:358-367
286. Woolley ML, Waters KA, Reavill C, Bull S., Lacroix LP, Martyn AJ, Hutcheson DM, Valerio E, Bate S., Jones DN, Dawson LA (2008) Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in rat. Behav Pharmacol 19:765-776
287. Yonelinas AP, Aly M, Wang W.C., Koen J.D. (2010) Recollection and familiarity: examining controversial assumptions and new directions. Hippocampus 20:1178-1194
288. Young JW, Powell SB, Risbrough V, Marston H.M., Geyer M.A. (2009) Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 122:150-202
289. Zamberletti E, Vigano D, Guidali C., Rubino T, Parolaro D. (2010) Long-lasting recovery of psychotic-like symptoms in isolation-reared rats after chronic but not acute treatment with the cannabinoid antagonist AM251. Int J Neuropsychopharmacol: 1-14.
290. Zanassi P, Paolillo M, Feliciello A., Avvedimento EV, Gallo V, Schinelli S. (2001) cAMP-dependent protein kinase induces cAMP-response element-binding protein phosphorylation via an intracellular calcium release/ERK-dependent pathway in striatal neurons. J Biol Chem 276:11487-11495
291. Zhang Z, Sun J, Reynolds G.P. (2002) A selective reduction in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia patients. Chin Med J (Engl) 115:819-823